Pharmacological prevention of eNOS uncoupling

Area of Science:

• Vascular Biology
• Cardiovascular Pharmacology
• Oxidative Stress

Background:

• Endothelial nitric oxide synthase (eNOS) produces protective nitric oxide (NO) under physiological conditions.
• Cardiovascular risk factors induce oxidative stress, leading to tetrahydrobiopterin (BH4) oxidation and eNOS uncoupling.
• eNOS uncoupling converts the enzyme into a superoxide producer, reducing NO bioavailability and exacerbating oxidative stress, contributing to cardiovascular pathology.

Purpose of the Study:

• To explore pharmacological strategies for preventing or reversing eNOS uncoupling.
• To identify therapeutic agents with the potential to improve endothelial function in the context of oxidative stress.

Main Methods:

• Review of experimental studies investigating the effects of various compounds on eNOS coupling and endothelial function.
• Analysis of drugs in clinical use and other agents for their potential to counteract eNOS uncoupling.

Main Results:

• Several drugs, including aliskiren, ACE inhibitors, AT1 receptor blockers, eplerenone, statins, nebivolol, and pentaerithrityl tetranitrate, have shown potential in experimental models to prevent or reverse eNOS uncoupling.
• Compounds like resveratrol, BH4, sepiapterin, folic acid, and AVE3085 have also demonstrated efficacy in recoupling eNOS and improving endothelial function.

Conclusions:

• Pharmacological approaches targeting eNOS uncoupling are of significant therapeutic interest for cardiovascular diseases.
• While promising, the long-term clinical benefits of these interventions remain under investigation and require further validation.